

Interrupting vaccination policies can greatly spread SARS-CoV-2 and enhance mortality from COVID-19 disease: the AstraZeneca case for France and Italy

Davide Faranda, Tommaso Alberti, Maxence Arutkin, Valerio Lembo, Valerio

Lucarini

► To cite this version:

Davide Faranda, Tommaso Alberti, Maxence Arutkin, Valerio Lembo, Valerio Lucarini. Interrupting vaccination policies can greatly spread SARS-CoV-2 and enhance mortality from COVID-19 disease: the AstraZeneca case for France and Italy. Chaos: An Interdisciplinary Journal of Nonlinear Science, 2021, 31, pp.041105. 10.1063/5.0050887. hal-03172578v1

HAL Id: hal-03172578 https://hal.science/hal-03172578v1

Submitted on 17 Mar 2021 (v1), last revised 6 May 2021 (v2)

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	Interrupting vaccination policies can greatly spread SARS-CoV-2		
2	and enhance mortality from COVID-19 disease: the AstraZeneca		
3	case for France and Italy		
4	Davide Faranda [*]		
5	Laboratoire des Sciences du Climat et de l'Environnement,		
6	CEA Saclay l'Orme des Merisiers, UMR 8212 CEA-CNRS-UVSQ,		
7	Université Paris-Saclay & IPSL, 91191, Gif-sur-Yvette, France.		
8	London Mathematical Laboratory, 8 Margravine Gardens, London, W6 8RH, UK. and		
9	LMD/IPSL, Ecole Normale Superieure,		
10	PSL research University, 75005, Paris, France.		
11	Tommaso Alberti		
12	National Institute for Astrophysics-Institute for		
13	Space Astrophysics and Planetology (INAF-IAPS),		
14	via del Fosso del Cavaliere 100, 00133, Rome, Italy.		
15	Maxence Arutkin		
16	UMR CNRS 7083 Gulliver, ESPCI Paris,		
17	10 rue Vauquelin, 75005 Paris, France.		
18	Valerio Lembo		
19	National Research Council of Italy,		
20	Institute of Atmospheric Sciences and Climate (CNR-ISAC), Bologna, Italy.		
21	Valerio Lucarini		
22	Department of Mathematics and Statistics,		
23	University of Reading, Reading, UK. and		
24	Centre for the Mathematics of Planet Earth,		
25	University of Reading, Reading, UK.		

(Dated: March 17, 2021)

26

Abstract

Several European countries have suspended the inoculation of the AstraZeneca vaccine out of suspicion of causing deep vein thrombosis. In this letter we report some Fermi estimates performed using a stochastic model aimed at making a risk-benefit analysis of the interruption of the delivery of the AstraZeneca vaccine in France and Italy. Our results clearly show that excess deaths due to the interruption of the vaccination campaign injections largely overrun those due to thrombosis even in worst case scenarios of frequency and gravity of the vaccine side effects.

As of March 2021, the spread of the SARS-CoV-2 virus [1] has caused more than 120 34 millions infections worldwide with a total death toll of more than 2 millions. Up to the end 35 of 2020, the only effective measures to contain the spread of the virus were based on social 36 distancing, wearing face masks and more/less stringent lockdown [2–4]. Later on, a massive 37 vaccination campaign kicked off in several countries thanks to the availability of a variety 38 of vaccines (e.g., AstraZeneca, Johnson&Johnson, Moderna, Pfizer/BionTech, Sputnik V). 39 Such vaccines differ substantially in terms of efficacy, legal status, availability, and logistics 40 needed for their delivery to patients. According to various estimates [5], vaccinations would 41 produce a reduction in infections, and eventually yield to "herd immunity" when $\approx 70\%$ of 42 the population gets fully vaccinated. When such a large fraction of the population becomes 43 immune to the disease, its spread from person to person becomes very unlikely, and the 44 whole community becomes protected. By allowing for an earlier easing of non-medical 45 measures against the SARS-CoV-2 virus, vaccination is also expected to significantly reduce 46 the economical, social and psychological impacts of lockdown measures [6]. Those estimates 47 assume that there is no break in the supply of vaccines or any other suspension in the 48 procedure due to side effects from vaccination. Unfortunately, on March 15th 2021 several 49 European countries suspended the use of AstraZeneca COVID-19 vaccine as a precaution in 50 order to investigate the death of a few dozens of patients developing blood clots - associated 51 with Deep Vein Thrombosis (DVT) [7] - after such vaccine, despite no proof of causal link 52 between vaccination and DVT [8]. Health personnel who inoculated the vaccine to those who 53 died as a result of DVT are being investigated in Italy for manslaughter [9]. The contingent 54 situation with the widespread COVID-19 pandemic naturally raises the question of whether 55 a prolonged stop in vaccinations coming from adopting the precautionary principle [10] 56 * davide.faranda@cea.fr

27

could cause an excess mortality beyond that caused by the hypothetical side effects of 57 the vaccines. The European Medicines Agency (EMA) is currently assessing whether the 58 vaccine can continue to be used despite possibly causing this very rare side effect. In this 59 Letter we aim at exploring this issue by computing future COVID-19 epidemic scenarios by 60 comparing i) the excess mortality caused by reducing the vaccinations using the stochastic 61 Susceptible-Exposed-Infected-Recovered (SEIR) model [11], and ii) the estimates of the 62 possible casualties caused by side effects of a vaccine, namely those associated with DVT. 63 We remark that the additional, longer-term effect of the presence of higher infection rates, 64 i.e., the increased risk of virus mutations leading to possibly more malignant and/or more 65 infectious variants, is not included in our treatment. Our analysis focuses on France and 66 Italy, which have been among the countries that have been most severely impacted by the 67 COVID-19 pandemic [12]. An important remark follows. Our goal is not to provide an exact 68 estimate of both i) and ii) but rather to perform an order-of-magnitude comparison between 69 excess deaths resulting from different scenarios of vaccination policy. In other terms, we will 70 approach the problem by performing Fermi estimates [13] where the classical back-of-the-71 envelope calculations are performed via the SEIR model, which allows to take into account 72 the uncertainties in both model parameters and data. In nuce, we perform a counterfactual 73 analysis based on a story-line approach, which has become a powerful investigation method 74 for assessing risks coming from extreme events [14]. While the quantitative consolidation of 75 our results clearly requires extensive data analysis and modelling, our findings show with 76 a large confidence that excess deaths due to the interruption of the vaccination campaign 77 largely override those due to DVT even in the worst case scenarios of frequency and gravity 78 of the vaccine side effects. Fermi estimates can provide valuable input for an efficient and 79 pragmatic application of the precautionary principle able to reduce the negative impacts of 80 hazards of various nature, as done in economics [15]. 81

The model [16] with time-dependent control parameters can mimic the dependence additional/external factors such as variability in the detected cases, different physiological response to the virus, release or reinforcement of distancing measures[11]. Our compartmental model [17] divides the population into four groups, namely, Susceptible (S), Exposed (E), Infected (I), and Recovered (R) individuals, according to the following evolution equations:

$$S_{t+1} = S_t - \lambda (1 - \alpha) \frac{I_t S_t}{N_t} - \lambda \alpha (1 - \sigma) \frac{I_t S_t}{N_t} + (1 - \sigma \alpha) S_t$$
(1)

$$E_{t+1} = E_t + \lambda \left(1 - \alpha\right) \frac{I_t S_t}{N_t} + \lambda \alpha \left(1 - \sigma\right) \frac{I_t S_t}{N_t}$$

$$+ (1 - \epsilon) E_t \tag{2}$$

$$I_{t+1} = I_t + \epsilon E_t + (1 - \alpha - \beta)I_t \tag{3}$$

$$R_{t+1} = R_t + \sigma \alpha S_t + \beta I_t \tag{4}$$

In the SEIR model above, the classical parameters are the recovery rate (β), the inverse 87 of the incubation period (ϵ), and the infection rate (λ). Here we have generalized the the 88 model presented in [11] by introducing two additional parameters able to succinctly mimic 89 the strategies of a vaccination campaign, namely the vaccination rate per capita α and 90 the vaccine efficacy σ , see Sun and Hsieh [18]. To consider uncertainties in long-term 91 extrapolations and time-dependent control parameters a stochastic approach is used though 92 which the control parameters $\kappa \in \{\alpha, \beta, \epsilon, \lambda, \sigma\}$ are described by an Ornstein-Uhlenbeck 93 process [19] with drift as follows: 94

95

$$\mathrm{d}\kappa = -\kappa(t)\mathrm{d}t + \kappa_0\mathrm{d}t + \varsigma_\kappa dW_t,\tag{5}$$

where $\kappa_0 \in \{\alpha_0, \beta_0, \epsilon_0, \lambda_0, \sigma_0\}, dW_t$ is the increment of a Wiener process. We re-96 mind that the basic reproduction number [20] is written $R_0 = \beta_0 / \lambda_0$. In Eqs. (1)-(5)97 we set dt = 1, which is the highest time resolution available for official COVID-19– 98 related counts and is relatively small compared to the characteristic times associated 99 with COVID-19 infection, incubation, and recovery/death. In our simulations we set 100 $\{\alpha_0, \beta_0, \epsilon_0, \sigma_0\} = \{0.0015, 0.37, 0.27, 0.59\}; \{\varsigma_\alpha, \varsigma_\beta, \varsigma_\epsilon, \varsigma_\sigma\} = \{0.25, 0.2, 0.2, 0.1\} \text{ a mortality}$ 101 rate $m_0 = 0.015$ [21]. While β_0 and ϵ_0 and the associated ς are the same as in [11], the 102 values of σ_0 and respective ς are derived from the range given for the AstraZeneca vaccine 103 phase 3 tests for the first dose [22] and α_0 and ς_{α} supposing that both Italy and France 104 keep vaccinating 10^5 individuals per day with a 20% daily fluctuation [23]. As in [11], we 105 also set $\varsigma_{\lambda} = 0.2$ allowing for 20% daily fluctuations in the infection rate. Note that here 106 we restrict to Gaussian fluctuations: as shown in [11], allowing for log-normal fluctuations 107

of the parameters does not change the average results but slightly enhance their dispersion.
See Supplementary Material for the numerical code.

Figure 1 reports the daily number of deaths $m_0 \times I(t)$ as a function of time for Italy (a) and 110 France (b). Initial conditions are set for both countries to the values reported on March 15th 111 as follows: for Italy we set $N = 60 \cdot 10^6$ population, $E(t) = I(t) = 20 \cdot 10^4$ as the infected 112 and exposed populations, $R(t) = 11 \cdot 10^6$ as the sum of $9 \cdot 10^6$ recovered estimated from 113 serologic tests and $2 \cdot 10^6$ immunized from 2 doses of either Pfizer/BioNTech, Moderna or 114 AstraZeneca vaccines and $R_0 = 1.16$. For France we set $N = 67 \cdot 10^6$, $E(t) = I(t) = 25 \cdot 10^4$, 115 $R(t) = 13.2 \cdot 10^6$ as the sum of $11 \cdot 10^6$ recovered estimated from serologic tests and $2.2 \cdot 10^6$ 116 immunized from vaccines and $R_0 = 1.02$. For both France and Italy, we assume that the 117 virus, after the second wave, has infected the 15% of the population. This estimates are 118 based on Pullano et al. [24] who reported a $7\% \pm 3\%$ total infections for France after the 119 first wave, assuming that the second wave had a similar magnitude for both countries. We 120 remark however, that our results are basically insensitive to oscillation of S(1) of order of 121 5 millions individuals (cfr. Supplementary Material Figure S1). Rather than integrating 122 the Fokker-Planck equation [25] corresponding to the system of equations given above, we 123 follow a Monte Carlo approach and we perform two sets of $N_r = 1000$ realizations (see 124 supplementary material Figure S2 for a justification of this value): stopping (red) and 125 continuing (blue) the vaccination campaign at the same rate. The model is integrated for 126 500 days, that is about the time it would take to vaccine the rest of the susceptible population 127 with AstraZeneca at the rate of 10^5 individuals per day. 128

First, we observe a monotonic decrease in the daily deaths for all scenarios considered 130 from the initial date $t = t_0$ corresponding to March 15, 2021. This is in agreement with 131 actual estimates that for Italy and France the so-called third wave should reach its peak by 132 the end of March, 2021 [26]. Moreover, we observe that the cumulative number of deaths 133 significantly reduce if vaccinations are continued at 100000 doses per day with respect to the 134 scenario where vaccination is stopped. For Italy (France) completely halting the vaccination, 135 at the actual epidemic rate, the number of excess deaths from COVID19 would amount to 136 $9 \pm 3 \cdot 10^3 (1.2 \pm 0.4 \cdot 10^3)$ excess deaths from COVID19. The difference between the two 137 countries is largely due to the value of R_0 , which is larger for Italy. This suggests that 138 halting vaccination in a growing epidemics phase (Italy) has more dramatic consequences 139 than in a more controlled scenario of $R_0 \approx 1$ (France). 140




FIG. 1. The number of daily deaths $m \times I(t)$ as a function of time (300 out of 500 days shown) for Italy (a) and France (b) using the values of $R_0 = 1.16$ (Italy) and $R_0 = 1.02$ reported respectively for the 15th of March countries. Solid lines show the ensemble average, dotted lines extend to one standard deviation of the mean. Red and blue curves refer respectively to no vaccination and a vaccination campaign whose efficacy is 59%.

Our previous analysis is based on a total stop of AstraZeneca vaccination. However, a 141 more realistic scenario is to assume that AstraZeneca vaccination will resume after a limited 142 number of days used for verification. We investigate this effect in Fig. 2. There we consider 143 the average excess deaths as a function of the interruption length in number of days (x-axis) 144 and R_0 (y-axis) for Italy (a) and France (b). The excess deaths are computed with respect 145 to a base scenario where vaccine injections are never interrupted and they are averaged over 146 1000 realizations of the SEIR model. Figure 2 shows that the longer is the vaccine injections 147 disruption, the higher is the number of excess deaths. The impact is stronger for higher 148 values of R_0 . A focus on the actual values for Italy and France is reported in Fig. 3. 149

The final step in our investigation is to compare the previous estimates of excess deaths with an order of magnitude estimate of deaths due to DVT resulting from side effects of the AstraZeneca vaccine. In order to make a meaningful comparison, in a case where




FIG. 2. Average over $N_r = 1000$ realizations of the stochastic SEIR model showing the excess deaths $m \times I(t)$ as a function of the number of the days of interruption of AstraZeneca vaccinations (x-axis) and R_0 (y-axis) for Italy (a) and France (b). The excess deaths are computed with respect to a base scenario where vaccine injections are never interrupted. Arrows indicate the values of R_0 chosen for Figs. 1-3. Each realization of the SEIR model is integrated for 500 days.

uncertainties are very large and hard to quantify, we will consider a worst case scenario for the impacts of the side effects. This scenario relies on the unrealistic hypothesis that the totality of susceptible population to DVT suffers from DVT shortly after being vaccinated, and the lethality rate is similar to the one observed in the overall population.

As of March 15th 2021, 30 suspect cases of DVT have been reported over a number of 5 millions vaccinated people with AstraZeneca in Europe[27]. By suspect cases we mean people who have developed DVT in the few days following the vaccination. This leads us to an estimate of a frequency of 6 cases per million of vaccines. Let's call this rate r_{AZ}^{DVT} . Let's also consider that in the case of France the incidence of DVT has been estimated to 1800




FIG. 3. Average over $N_r = 1000$ realizations (same as those presented in Fig. 2) of the stochastic SEIR model showing the excess deaths $m \times I(t)$ as a function of the number of the days of interruption of AstraZeneca vaccinations for Italy $R_0 = 1.16$ (a) and France $R_0 = 1.02$ (b) with . Error bars are computed as the mean relative error.

people per 1 million inhabitants per year ([28]), with a lethality rate after three months of 162 5% [29], raising to 30% when a period of 5 years is considered [7]. This leads to estimating 163 a total of the order of 10000 deaths per year as a result of DVT. Even assuming that all the 164 DVT cases following the inoculation of the AstraZeneca vaccine would have not manifested 165 themselves in absence of the injection, we have that N vaccination would lead to an extra 166 $N \times r_{AZ}^{DVT}$ DVT cases. Let's assume that all of these cases result into death[30]. We then 167 have that 10^5 daily vaccination would result into a maximum of 0.6 daily death. In 500 days, 168 which is the time needed to cover the entire French population, this leads to an upper bound 169 of 300 deaths. Considering a death rate of 30%, the number scales down to approximately 170 100, while considering a death rate of 5% the number scales down to approximately 15. 171 Similar figures apply for Italy. 172

Decision-making in presence of strong uncertainties associated with health and environmental risks is an extremely complex process resulting from the interplay between science, politics, stakeholders, activists, lobbies, media, and society at large [31–33]. In this letter we

have aimed at contributing to the debate on different strategies for combating, in conditions 176 of great uncertainties in terms of health and social response, pandemic like the current one 177 caused by the SARS-CoV-2 virus. We have focused on the case of the AstraZeneca COVID-178 19 vaccine and on the locales of Italy and France, for the period starting on March 15th 179 2021. Here, the goal is provide a semi-quantitative comparison, based on Fermi estimates 180 informed by a simple vet robust stochastic model, between the excess deaths due to tempo-181 ral restriction to the deployment of a still experimental vaccine with respect to the excess 182 deaths due to its possible side effects. Given the many uncertainties on the (possible) side 183 effects of the vaccine, we have resorted to making worst case scenario calculations in order 184 to provide a robust upper bound to the related excess deaths. Our results are preliminary 185 and should be supplemented by more detailed modelling and data collection exercises. Our 186 results are preliminary and should be supplemented by more detailed modelling and data 187 collection exercises. Indeed: i) we assume a single vaccine with the nominal AstraZeneca 188 efficacy, neglecting the other available vaccines, ii) we consider a fixed vaccination rate, iii) 189 for AstraZeneca DVT side effects we consider French data and rescale them for the Italian 190 populations, iv) we focused our analysis on DVT side effects, but other pathologies could be 191 considered with the same approach. Yet, they clearly suggest - see a useful summary in Ta-192 ble I - that the benefits of deploying the vaccine greatly outweight the associated risks, and 193 that the relative benefits are wider in situations where the reproduction number is larger, 194 and they increase with the temporal duration of the vaccine ban. 195

196 ACKNOWLEDGEMENTS

This work has been greatly supported by the London Mathematical Laboratory and we acknowledge the logistic support of SCuP. VLu acknowledges the support received from the EPSRC project EP/T018178/1 and from he EU Horizon 2020 project TiPES (Grant no. 820970).

^[1] J. Wu, W. Cai, D. Watkins, and J. Glanz, How the virus got out, The New York Times (2020).

Excess Deaths	Italy	France
Stop AZ for $t = 500$ days	9000 ± 3000	1200 ± 400
Stop AZ for $t = 14$ days	1700 ± 500	430 ± 70
Stop AZ for $t = 7$ days	790 ± 90	160 ± 30
Stop AZ for $t = 3$ days	260 ± 50	130 ± 20
Worst case DVT deaths due to AZ	≈ 280	≈ 300
High fatality DVT deaths due to AZ	≈ 90	≈ 100
Standard fatality DVT deaths due to AZ	≈ 13	≈ 15

TABLE I. The first 4 lines of the table indicate the excess deaths due to the interruption of AstraZeneca compared to a reference scenario where the vaccine injections are never interrupted. The SEIR model is integrated for 500 days with $R_0 = 1.16$ for Italy and $R_0 = 1.02$ for France. The last 3 rows of the table show the deaths from deep vein thrombosis (DVT) that could be due to the vaccine in three different scenarios: the worst case (100% mortality rate), a high mortality scenario (death rate of 30%) and a standard mortality scenario (5% mortality rate) assuming a period of 500 days.

- [2] R. M. Anderson, H. Heesterbeek, D. Klinkenberg, and T. D. Hollingsworth, How will country based mitigation measures influence the course of the covid-19 epidemic?, The Lancet **395**,
 931 (2020).
- [3] M. Chinazzi, J. T. Davis, M. Ajelli, C. Gioannini, M. Litvinova, S. Merler, A. Pastore y Piontti, K. Mu, L. Rossi, K. Sun, C. Viboud, X. Xiong, H. Yu, M. E.
 Halloran, I. M. Longini, and A. Vespignani, The effect of travel restrictions on the
 spread of the 2019 novel coronavirus (covid-19) outbreak, Science 368, 395 (2020),
 https://science.sciencemag.org/content/368/6489/395.full.pdf.
- [4] H.-Y. Yuan, G. Han, H. Yuan, S. Pfeiffer, A. Mao, L. Wu, and D. Pfeiffer, The importance of the timing of quarantine measures before symptom onset to prevent covid-19 outbreaks illustrated by hong kong's intervention model, medRxiv 10.1101/2020.05.03.20089482 (2020),
- https://www.medrxiv.org/content/early/2020/05/06/2020.05.03.20089482.full.pdf.
- [5] D. Sridhar and D. Gurdasani, Herd immunity by infection is not an option, Science **371**, 230
- (2021), https://science.sciencemag.org/content/371/6526/230.full.pdf.

- [6] N. Fernandes, Economic effects of coronavirus outbreak (covid-19) on the world economy,
 Available at SSRN 3557504 (2020).
- [7] M. Cushman, Epidemiology and risk factors for venous thrombosis, Seminars in hematology
 44, 62 (2007).
- [8] Https://apnews.com/article/germany-suspends-astrazeneca-vaccine-blood-clotting-
- 222 0ab2c4fe13370c96c873e896387eb92f.
- [9] Https://www.ansa.it/english/news/general_news/2021/03/15/aifa-stops-astrazeneca-jab-as-
- precautionary-measure_5114cf0b-2575-4ea7-8eb7-9bd556a435c5.html.
- [10] K. Steele, The precautionary principle: a new approach to public decisionmaking?, Law, Probability and Risk 5, 19 (2006), https://academic.oup.com/lpr/articlepdf/5/1/19/6207484/mgl010.pdf.
- [11] D. Faranda and T. Alberti, Modeling the second wave of COVID-19 infections in France and
 Italy via a stochastic SEIR model, Chaos 30, 111101 (2020), arXiv:2006.05081 [q-bio.PE].
- ²³⁰ [12] T. Alberti and D. Faranda, On the uncertainty of real-time predictions of epidemic growths: A
- covid-19 case study for china and italy, Communications in Nonlinear Science and Numerical
 Simulation 90, 105372 (2020).
- [13] S. Mahajan, The Art of Insight in Science and Engineering: Mastering Complexity (The MIT
 Press, Cambridge, USA, 2014).
- [14] T. G. Shepherd, A common framework for approaches to extreme event attribution, Current
 Climate Change Reports 2, 28 (2016).
- P. M. Anderson and C. A. Sherman, Applying the fermi estimation technique to business
 problems., Journal of Applied Business & Economics 10 (2010).
- [16] D. Faranda, I. P. Castillo, O. Hulme, A. Jezequel, J. S. W. Lamb, Y. Sato, and E. L. Thompson, Asymptotic estimates of sars-cov-2 infection counts and their sensitivity to stochastic perturbation, Chaos: An Interdisciplinary Journal of Nonlinear Science **30**, 051107 (2020), https://doi.org/10.1063/5.0008834.
- [17] F. Brauer, Compartmental models in epidemiology, in *Mathematical epidemiology* (Springer, 2008) pp. 19–79.
- [18] C. Sun and Y.-H. Hsieh, Global analysis of an seir model with varying population size and
 vaccination, Applied Mathematical Modelling 34, 2685 (2010).

- [19] G. E. Uhlenbeck and L. S. Ornstein, On the theory of the brownian motion, Phys. Rev. 36, 823 (1930).
- [20] Paul L. Delamater et al., Complexity of the basic reproduction number (r0) volume 25,
 number 1-january 2019 emerging infectious diseases journal cdc (2019).
- [21] D. Fanelli and F. Piazza, Analysis and forecast of COVID-19 spreading in China, Italy and
 France, Chaos Solitons and Fractals 134, 109761 (2020), arXiv:2003.06031 [q-bio.PE].
- ²⁵³ [22] Merryn Voysey et al., Safety and efficacy of the chadox1 ncov-19 vaccine (azd1222) against
- sars-cov-2: an interim analysis of four randomised controlled trials in brazil, south africa, and
 the uk, *The Lancet*, The Lancet **397**, 99 (2021).
- ²⁵⁶ [23] L. Salvioli, Il vaccino anti covid in italia in tempo reale: Il sole 24 ore (2021).
- ²⁵⁷ [24] G. Pullano, L. Di Domenico, C. E. Sabbatini, E. Valdano, C. Turbelin, M. Debin, C. Guerrisi,
- C. Kengne-Kuetche, C. Souty, T. Hanslik, *et al.*, Underdetection of cases of covid-19 in france
 threatens epidemic control, Nature 590, 134 (2021).
- ²⁶⁰ [25] H. Risken, *The Fokker-Planck equation* (Springer, Berlin, 1996).
- ²⁶¹ [26] Third covid wave sweeps across eu and forces new restrictions (2021).
- ²⁶² [27] Here, we use European data accessible at [34] to average out the large spread of national data.
- ²⁶³ [28] S. Bouée, C. Emery, A. Samson, J. Gourmelen, C. Bailly, and F.-E. Cotté, Incidence of venous
- thromboembolism in France: a retrospective analysis of a national insurance claims database,
 Thrombosis Journal 14, 4 (2016).
- [29] J. A. Heit, Epidemiology of venous thromboembolism, Nature Reviews Cardiology 12, 464
 (2015).
- ²⁶⁸ [30] Current data suggest that this is manifestly a gross worst case approximation.
- [31] Anonymous, Agu statement: Investigation of scientists and officials in l'aquila,
 italy, is unfounded, Eos, Transactions American Geophysical Union 91, 248 (2010),
 https://agupubs.onlinelibrary.wiley.com/doi/pdf/10.1029/2010EO280005.
- [32] A. Benessia and B. De Marchi, When the earth shakes ... and science with it. the management
 and communication of uncertainty in the l'aquila earthquake, Futures 91, 35 (2017), postNormal science in practice.
- [33] J. Reis and P. S. Spencer, Decision-making under uncertainty in environmental health policy:
 new approaches, Environmental Health and Preventive Medicine 24, 57 (2019).

- 277 [34] Covid-19 vaccine astrazeneca: Prac investigating cases of thromboembolic events vaccine's
- ²⁷⁸ benefits currently still outweigh risks update european medicines agency, European Medicines
- Agency (2021).